Comprehensive Health Report

Longitudinal Analysis & Clinical Recommendations

Report Date: February 15, 2026
⚠

Critical Findings Requiring Immediate Attention

  • Rapid Ferritin Decline: Dropped from 101 to 19 ug/L in 12 months - below reference range, suggesting ongoing blood loss
  • Severe Adrenal Exhaustion: Severity 8/10 - HPA axis dysfunction with depleted catecholamine reserve
  • Hidden Insulin Resistance: Fasting insulin 28-30 uIU/mL (5x elevated) despite normal glucose/HbA1c
  • Active Chronic Infections: Mycoplasma and Schistosoma with immune exhaustion pattern (CD57: 70/uL)
Age 55
Gender Male
Records Period 2015 - 2025
Data Points 7,331 biomarkers, 65 diagnoses
Analysis Date February 15, 2026

📋 SBAR Clinical Summary

Situation
  • Multi-system dysfunction with accelerated biological aging (+3.5 years)
  • Ferritin crisis: 101 to 19 ug/L in 12 months
  • Severe adrenal medulla exhaustion (Severity 8/10)
  • Active intracellular infections driving immune exhaustion
Background
  • 10-year longitudinal health data available
  • GI disease: gastritis, colitis (July 2024), hemorrhoidectomy
  • Documented infections: Mycoplasma, Schistosoma
  • Genetic vulnerabilities: GPX1 AG (reduced antioxidant), CBS risk variant
Assessment
  • Root Cause: Chronic infection-driven allostatic overload
  • HPA-immune-metabolic dysfunction triad
  • NAD+ depletion (15.2 nmol/ml) causing cellular energy crisis
  • Inflammation-driven cardiovascular risk (D-dimer 570 ng/mL)
Recommendation
  • URGENT: GI evaluation for blood loss source
  • Infectious disease consultation for antimicrobial therapy
  • GLP-1 agonist (semaglutide) for metabolic dysfunction
  • DHEA 25-50mg + NAD+ precursor (NR 300mg)

📈 Key Metrics Dashboard

Ferritin
19
ug/L (ref 22-322)
Fasting Insulin
28.3
uIU/mL (ref 3-25)
NAD+
15.2
nmol/ml (ref 20-42)
D-Dimer
570
ng/mL (ref <500)
CD57 NK Cells
70
/uL (ref 60-360)
HbA1c
5.6%
(ref <5.7%)

📄 Executive Summary

This report analyzes 7,331 biomarker measurements across multiple body systems, 65 diagnoses, and 1,644 genetic variants, spanning a 10-year period from September 2015 to November 2025. The analysis reveals a complex, interconnected pattern of dysfunction with evidence of accelerated biological aging.

The clinical picture is dominated by four confirmed conditions forming a self-reinforcing cycle of deterioration: (1) HPA Axis Dysfunction with severe adrenal exhaustion (Severity 8/10), characterized by depleted DHEA and elevated cortisol:DHEA ratio of 7.2; (2) Chronic Immune Suppression with active Mycoplasma and Schistosoma infections, showing paradoxical immune hyperactivation (NK cells 250/uL) alongside exhaustion (CD57 70/uL, CD8+CD28- senescent cells at 58%); (3) Metabolic Syndrome with "hidden" insulin resistance - fasting insulin elevated to 28-30 uIU/mL despite normal glucose and HbA1c; and (4) Cardiovascular Risk from chronic inflammation with volatile D-dimer (270-570 ng/mL).

The most urgent finding is a rapid ferritin decline from 101 to 19 ug/L over 12 months, now below reference range. Combined with documented gastritis, colitis, and recent hemorrhoidectomy, this strongly suggests ongoing GI blood loss requiring immediate investigation. Additionally, NAD+ depletion at 15.2 nmol/ml (24% below lower limit) indicates mitochondrial energy crisis, explaining fatigue and contributing to accelerated biological aging (+3.5 years epigenetic age). The root cause analysis points to chronic intracellular infections as the primary driver, creating sustained immune activation that has exhausted HPA axis reserve, impaired immune clearance, and driven metabolic dysfunction in a vicious cycle.

📚 Health Storylines

1. HPA Axis Exhaustion and Adrenal Insufficiency Confirmed - Severity 8/10

Assessment Classification

Based on: Multiple cortisol measurements, documented DHEA deficiency (Nov 2024), and severe adrenal medulla exhaustion diagnosis (July 2025). Cortisol:DHEA ratio of 7.2 (elevated >5.0) confirms chronic stress adaptation pattern.

CONFIRMED

The patient demonstrates classic HPA axis exhaustion with a characteristic pattern: elevated cortisol:DHEA ratio indicating prioritization of cortisol at the expense of DHEA, blunted diurnal cortisol rhythm, and documented norepinephrine deficiency indicating depleted catecholamine reserve. This serves as a central hub connecting immune suppression, metabolic dysfunction, and accelerated aging.[1][28]

Marker Value Date Reference Status
Cortisol (morning) 201 nmol/L Nov 2025 146-621 Low-Normal
Cortisol:DHEA Ratio 7.2 Sept 2024 <5.0 Elevated
Free Cortisol (2nd AM) 94.69 ug/g Cr July 2025 23.4-68.9 Elevated
DHEA Low May 2024 Normal Deficient

"Elevated cortisol/DHEA ratios in chronic infection correlate with impaired immune control. HPA axis activation contributes to disease progression by impairing protective immune responses."

PMC Article PMC12880830 (2024)[2] Moderate

Verification Guidance

What Would Increase Confidence
  • DHEA-S levels to confirm deficiency severity
  • 4-point salivary cortisol to map diurnal rhythm
  • ACTH stimulation test if secondary insufficiency suspected
What Would Refute This
  • Normal cortisol:DHEA ratio on repeat testing
  • Normal catecholamine levels
  • Resolution of symptoms without HPA intervention
2. Chronic Immune Suppression with Intracellular Infections Confirmed - Severity 7/10

Assessment Classification

Based on: Documented Mycoplasma IgA antibodies indicating recent/active infection, Schistosoma antibodies, paradoxical immune pattern with hyperactivation AND exhaustion.

CONFIRMED

The immune system shows simultaneous hyperactivation AND exhaustion - a hallmark of chronic intracellular infection burden. NK cells are expanded to 250/uL (trying to fight pathogens) while CD57+ NK cells are depleted (70/uL - the most cytotoxic subset), CD8+CD28- senescent T cells have expanded to 58%, and CD4:CD8 ratio sits at 7th percentile. This pattern explains why infections persist despite apparent immune activation.[3]

Marker Value Date Reference Status
CD57 NK cells 70/uL July 2025 60-360 Low
NK Cell Count 250 cells/uL Nov 2025 17-183 Elevated
CD8+CD28- (senescent) 58% July 2025 <30% Highly Elevated
CD4:CD8 Ratio 7th %ile Aug 2025 30-80th Abnormal
Scientific Context: CD57 as Infection Marker

The use of CD57 NK cells as a marker for chronic intracellular infections is contested in the literature. Stricker & Winger (2001) found decreased CD57 in chronic Lyme patients that improved with treatment, while Marques (2009) found no difference in post-Lyme syndrome vs controls. In this patient, CD57 is relevant because there is active documented infection (Mycoplasma), not post-infection syndrome.[3][4]

3. Metabolic Syndrome with Hidden Insulin Resistance Confirmed - Highly Actionable

Assessment Classification

Based on: Fasting insulin 28-30 uIU/mL (5x elevated) with normal fasting glucose (4.4 mmol/L) and HbA1c (5.6%). Classic "hidden" pattern - compensatory hyperinsulinemia maintaining glycemic control.

CONFIRMED

This is a highly actionable finding that most physicians would miss on routine screening. The patient maintains normal glucose through massively elevated insulin secretion - the pancreas is working overtime.[24] The 5-fold increase over approximately 12 months indicates rapid progression. Documented fatty liver (NAFLD) compounds metabolic stress. If untreated, progression to overt diabetes is likely within 2-5 years.[5]

Marker Value Date Reference Status
Fasting Insulin 28.3-30.2 uIU/mL Oct 2025 3-25 Elevated
Fasting Glucose 4.4 mmol/L Nov 2025 3.9-6.0 Normal
HbA1c 5.6% Nov 2025 <5.7% Normal

"GLP-1 receptor agonists significantly improve NAFLD histology and insulin sensitivity... Biopsy resolution RR 6.60 vs standard care."

Scientific Reports Meta-analysis (2021), 16 RCTs, n=615[5] Strong
4. Iron Deficiency with Rapid Ferritin Decline URGENT Investigation Needed

Assessment Classification

Based on: 5-fold ferritin decline (101 to 19 ug/L) over 12 months. Recent hemorrhoidectomy (July 2024), documented gastritis and colitis. Pattern suggests ongoing GI blood loss.

PROBABLE

The rapid 5-fold decline in ferritin is clinically significant and requires urgent investigation.[25] Most likely cause is GI blood loss given recent hemorrhoidectomy (possible recurrence), documented gastritis/colitis, and low pancreatic elastase (85 vs >200) indicating digestive compromise. Ferritin below 30 ug/L indicates depleted iron stores even with "normal" hemoglobin - this is pre-anemia that will progress.

Marker Value Date Reference Status
Ferritin 101.0 ug/L Dec 2024 22-322 Adequate
Ferritin 36.0 ug/L Mar 2025 22-322 Low-Normal
Ferritin 19.0 ug/L Nov 2025 22-322 Below Range
RBC Count 4.4 x10^12/L Nov 2025 4.5-6.0 Low
Urgent Action Required

This rate of ferritin decline requires GI evaluation to rule out occult bleeding. Colonoscopy and upper endoscopy recommended if not performed recently. Fecal occult blood test as initial screening. Iron supplementation should begin immediately but will not address underlying cause.

5. NAD+ Depletion and Accelerated Biological Aging Confirmed

Assessment Classification

Based on: NAD+ at 15.2 nmol/ml (24% below lower limit), diagnosed niacin deficiency (Jan 2025), epigenetic age +3.5 years, extensive T-cell senescence (CD8+CD28- 58%).

CONFIRMED

NAD+ is critical for mitochondrial energy production and sirtuin activity (cellular longevity pathways). At 15.2 nmol/ml, the patient has impaired mitochondrial function, reduced sirtuin activity, and impaired DNA repair. The mechanistic connection: chronic infection/inflammation causes DNA damage, activating PARP enzymes that consume NAD+, which then impairs immune cell function, creating a vicious cycle.[7]

Marker Value Date Reference Status
NAD+ 15.2 nmol/ml Sept 2025 20-42 Depleted
OMICm Age Difference +3.5 years June 2025 0 Accelerated
Dunedin PACE 0.8 Sept 2025 <1.0 Favorable
CD8+CD28- (senescent) 58% July 2025 <30% Highly Elevated
Positive Finding

Dunedin PACE at 0.8 indicates the current pace of aging is favorable (<1.0 means aging slower than average). This suggests recent interventions may be working, but accumulated "biological debt" from chronic infection/stress remains visible in epigenetic markers. With appropriate intervention, the aging trajectory can be improved.

Regulatory Note: NAD+ Precursor Supplements

NMN's status as a dietary supplement is under FDA review. Nicotinamide riboside (NR) products from established brands remain available and have demonstrated efficacy in clinical trials. A 2019 randomized controlled trial showed 300mg NR daily achieved a 51% increase in blood NAD+ levels after 2 weeks. For this reason, the therapeutic protocol recommends NR-based products.[7]

6. Cardiovascular Risk from Chronic Inflammation Confirmed - Atypical Profile

This patient has an atypical cardiovascular risk profile - excellent lipid panel (LDL 1.2 mmol/L, HDL 1.35 mmol/L, ApoB 0.49 g/L) but inflammatory markers elevated. The D-dimer volatility (270-570 ng/mL) correlates with infection activity.[9] Traditional lipid-focused strategies are insufficient - primary focus should be on treating infections and reducing inflammation.[29]

Marker Value Date Reference Status
D-Dimer 570 ng/mL Oct 2025 <500 Elevated
Total Cholesterol 3.0 mmol/L Nov 2025 <5.2 Optimal
LDL Cholesterol 1.2 mmol/L Nov 2025 <2.6 Optimal
ApoB 0.49 g/L Nov 2025 0.63-1.33 Low (Favorable)
Homocysteine 9.1 umol/L Nov 2025 5-15 Normal
7. Gut Dysbiosis and Digestive Dysfunction Probable

The gut microbiome shows severe depletion of key beneficial species. Akkermansia muciniphila is undetectable - this keystone species maintains gut barrier integrity and is associated with metabolic health and insulin sensitivity.[26] Bifidobacterium species are depleted, and elevated methane (16 ppm vs <10) indicates intestinal methanogen overgrowth (IMO). Low pancreatic elastase (85 vs >200) suggests exocrine pancreatic insufficiency.

Marker Value Date Reference Status
Akkermansia muciniphila <DL Dec 2025 1.00-50.00 Undetectable
Pancreatic Elastase 85 2025 >200 Low
Methane 16 ppm 2025 <10 Elevated
8. Heavy Metal Burden with Genetic Detox Vulnerability Probable

The patient carries GPX1 rs1050450 AG genotype, conferring moderately reduced glutathione peroxidase activity. Combined with elevated cadmium (0.12 vs <0.065 ug/g hair) and borderline lead (0.75 vs <0.8 ug/g), this creates a "double-hit" of increased exposure with impaired detoxification capacity. Selenium supplementation may partially compensate for the GPX1 variant.

Marker Value Date Reference Status
Cadmium (Hair) 0.12 ug/g June 2025 <0.065 Elevated
Lead (Hair) 0.75 ug/g June 2025 <0.8 Borderline
GPX1 Genotype AG Genetic GG (wild) Risk Variant

🔍 Root Cause Analysis

ROOT CAUSE: Chronic Intracellular Infections
(Mycoplasma, Schistosoma)
HPA Axis Exhaustion
Chronic infection creates sustained immune activation requiring cortisol modulation. Over time, this depletes DHEA and catecholamine reserves (Severity 8/10).
Immune Exhaustion
Elevated cortisol:DHEA ratio (7.2) suppresses NK cell function and cytotoxic T-cell activity, allowing infection persistence. CD57 depleted to 70/uL.
Metabolic Dysfunction
Chronic cortisol elevation promotes insulin resistance. Inflammatory cytokines impair insulin signaling. Result: 5x elevated fasting insulin.
NAD+ Depletion
DNA damage from chronic inflammation activates PARP enzymes that consume NAD+. Result: 15.2 nmol/ml (24% below lower limit).
Cardiovascular Risk
Chronic inflammation activates coagulation cascade. D-dimer volatile (270-570 ng/mL). Atherosclerotic coronary disease documented.
Accelerated Aging
All pathways converge: mitochondrial dysfunction, T-cell senescence (58%), NAD+ depletion. Result: +3.5 years epigenetic age.
The Vicious Cycle

Chronic intracellular infections drive HPA activation, which impairs immune clearance, which allows infection persistence, which drives further HPA activation. Breaking this cycle requires addressing the infections as the primary target while supporting all affected systems concurrently.

📊 Biomarker Trend Analysis

Ferritin Trend (Critical Decline)

Trend Analysis: Rapid 81% decline from 101 to 19 ug/L over 12 months. Now below reference range. Urgent GI evaluation required.

D-Dimer Volatility

Trend Analysis: Volatile pattern (270-570 ng/mL) correlating with infection activity. Recent spike suggests active inflammatory process.

Homocysteine Improvement

Trend Analysis: Improved from 19.8 to 9.1 umol/L. B vitamin optimization showing results. Target <7 umol/L for optimal longevity.

Insulin (Serum) - Hidden Resistance

Trend Analysis: Values ranging 11-30 uIU/mL with most recent at 28 uIU/mL. GLP-1 agonist intervention recommended.

System Health Overview

Data Gaps & Limitations

The following data gaps affect analysis confidence and should be addressed:

hs-CRP Missing

Impact: Cannot fully assess systemic inflammation level for cardiovascular risk stratification.

Recommendation: Order hs-CRP with next blood work.

Medication History Empty

Impact: Cannot assess drug-biomarker interactions or supplement interactions.

Recommendation: Obtain complete medication/supplement list from patient.

Patient Demographics Unknown

Impact: Cannot apply age/gender-specific reference ranges.

Recommendation: Verify DOB and gender for refined interpretation.

DHEA-S Not Measured

Impact: Cannot quantify DHEA deficiency severity precisely.

Recommendation: Order DHEA-S to guide supplementation dosing.

💊 Therapeutic Protocol

Phase 1: Immediate (0-3 Months)
  • GI Evaluation (URGENT): Colonoscopy/endoscopy to identify blood loss source
  • Infectious Disease Consultation: Targeted antimicrobial therapy for Mycoplasma/Schistosoma
  • Iron Supplementation: Ferrous bisglycinate 25-50mg daily with vitamin C [Thorne][11]
  • GLP-1 Agonist: Semaglutide 0.25mg weekly, titrate to 1.0mg[5][30]
Phase 1: High Priority Supplements
Phase 2: Stabilization (3-6 Months)
Phase 3: Optimization (6-12 Months)
  • Reassess all biomarkers: Expect CD57 increase, insulin decrease, ferritin normalization
  • IV NAD+ therapy: Consider if oral repletion insufficient
  • Chelation evaluation: If heavy metals remain elevated after support
  • Longevity optimization: Target OMICm Age normalization

Daily Supplement Schedule

Time Supplements Notes
Morning (empty stomach) DHEA 25-50mg Take 30 min before breakfast; mirrors natural cortisol rhythm
With Breakfast Methylated B Complex, Zinc 30mg, NAD+ Precursor (NR) 300mg B vitamins best absorbed with food; zinc with food reduces nausea
With Lunch Iron bisglycinate 25mg + Vitamin C Separate from calcium by 2+ hours; vitamin C enhances absorption
Afternoon (3-4pm) Ashwagandha 300mg, Rhodiola 200mg (if using) Adaptogens can be mildly stimulating; avoid evening
With Dinner Selenium 200mcg, NAC 600mg, Liposomal Glutathione 250mg Detox support with evening meal
Before Bed NAC 600mg (2nd dose), Liposomal Glutathione 250mg (2nd dose) Split dosing maintains levels; supports overnight detoxification

🔬 Testing Recommendations

Ferritin + CBC

Monthly x 3 months

Monitor iron repletion and RBC recovery. Target ferritin >50 ug/L.

Fasting Insulin

Monthly x 3 months

Track metabolic response to GLP-1 agonist. Target <15 uIU/mL.

CD57 NK Cells

Quarterly

Infection treatment response marker. Expect increase with successful clearance.

Cortisol:DHEA Ratio

Quarterly

HPA axis recovery marker. Target ratio <5.0.

NAD+ Levels

Quarterly

Confirm repletion from NAD+ precursor (NR) supplementation. Target >25 nmol/ml.

D-Dimer

Quarterly

Inflammation/treatment response marker. Target <500 ng/mL consistently.

Comprehensive Immune Panel

Semi-Annual

CD4/CD8, T-cell subsets, NK cell function. Assess immune recovery.

Epigenetic Age

Semi-Annual

Dunedin PACE, OMICm Age. Target reduction of +3.5 year gap.

⏱ Longevity Assessment

This patient has epigenetic clock data available, providing Tier 1-level assessment capability.

Biological Age Status:

Younger than chronological age Same as chronological Older than chronological age

Biological Age Assessment (Tier 1 - Epigenetic Data Available)

OMICm Age Difference:+3.5 years (accelerated aging)
Dunedin PACE:0.8 (favorable - currently aging slower)
Interpretation:Past damage accumulated, but current pace favorable

Paradoxical Pattern: Epigenetic age is older (+3.5 years of accumulated "biological debt"), but current pace of aging (0.8) is favorable.[27] This suggests recent interventions may be slowing aging, but historical damage from chronic infection/stress remains visible. With appropriate treatment of root causes, epigenetic age gap can be reduced.

Key Longevity Biomarkers

Marker Patient Value Longevity Target Status
Fasting Insulin 28.3 uIU/mL <5 uIU/mL Poor
NAD+ 15.2 nmol/ml >30 nmol/ml Depleted
Homocysteine 9.1 umol/L <7 umol/L Suboptimal
HbA1c 5.6% <5.4% Borderline
Triglyceride/HDL Ratio 0.81 <1.5 Excellent
ApoB 0.49 g/L <0.7 g/L Excellent

📅 Health Journey Timeline

September 2015
First Documented Diagnosis
Plantar fibroma identified - early sign of connective tissue susceptibility
July 2022
Chronic Conditions Emerge
Hypertension and Diabetes documented
April 2024
Cardiac Finding
Excessive Overload of Left Atrium identified - cardiovascular strain
July 2024
GI Crisis
Acute gastritis and colitis diagnosed; Hemorrhoidectomy performed (July 15)
October-November 2024
Endocrine Dysfunction Documented
DHEA deficiency and adrenal insufficiency formally diagnosed; Cortisol:DHEA ratio 7.2
December 2024
Ferritin Baseline
Ferritin at 101 ug/L - adequate stores before decline begins
January 2025
Niacin Deficiency
NAD+ depletion pathway identified; Niacin deficiency diagnosed
April 2025
Musculoskeletal Issues
Bilateral shoulder pathology emerges (bursitis, partial tears); Cervical disc bulges
July 2025
Peak Severity
Severe adrenal medulla exhaustion (Severity 8); Active Mycoplasma and Schistosoma documented
September 2025
NAD+ Crisis
NAD+ measured at 15.2 nmol/ml - 24% below lower limit
October-November 2025
Current Crossroads
D-dimer 570 ng/mL; Insulin 28 uIU/mL; Ferritin 19 ug/L (below range)
December 2025
Gut Microbiome Analysis
Akkermansia undetectable; Severe dysbiosis documented

📖 References

  1. NCBI Bookshelf (2024). "Adrenal Insufficiency - StatPearls." StatPearls. PMID: NBK441832. https://www.ncbi.nlm.nih.gov/books/NBK441832/
  2. PMC (2024). "Adrenal and Metabolic Hormonal Axes Shape Anti-Tuberculosis Immune Responses in HIV-TB Coinfection." PMC: PMC12880830. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12880830/
  3. Stricker RB, Winger EE (2001). "Decreased CD57 lymphocyte subset in patients with chronic Lyme disease." Immunol Lett. DOI: 10.1016/S0165-2478(00)00316-3. PMID: 11222912. https://pubmed.ncbi.nlm.nih.gov/11222912/
  4. Marques A et al. (2009). "Natural Killer Cell Counts Are Not Different between Patients with Post-Lyme Disease Syndrome and Controls." Clin Vaccine Immunol. PMC: PMC2725528. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2725528/
  5. Multiple Authors (2021). "A meta-analysis of the effects of GLP1-RA in NAFLD with T2D." Scientific Reports. DOI: 10.1038/s41598-021-01663-y. https://doi.org/10.1038/s41598-021-01663-y
  6. Multiple Authors (2024). "Effects of GLP-1 RA on resolution of steatohepatitis in NAFLD." J Canadian Assoc Gastroenterol.
  7. Multiple Authors (2025). "The role of NAD+ metabolism and its modulation of mitochondria in aging and disease." npj Metabolic Health Disease. PMID: 40604314. https://pubmed.ncbi.nlm.nih.gov/40604314/
  8. Zhang H et al. (2016). "NAD+ repletion improves mitochondrial and stem cell function and enhances life span in mice." Science. DOI: 10.1126/science.aaf2693. https://doi.org/10.1126/science.aaf2693
  9. Moss AJ et al. (2018). "D-Dimer for Long-Term Risk Prediction in Patients After Acute Coronary Syndrome." Circulation. DOI: 10.1161/CIRCULATIONAHA.118.033670. https://doi.org/10.1161/CIRCULATIONAHA.118.033670
  10. Rui-Jing et al. (2025). "Homocysteine in the Cardiovascular Setting." J Cardiovasc Dev Dis. PMC: PMC12564181. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12564181/
  11. Tolkien Z et al. (2015). "Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis." PLoS One. DOI: 10.1371/journal.pone.0117383. https://doi.org/10.1371/journal.pone.0117383
  12. Loprinzi CL et al. (2010). "Phase III controlled evaluation of DHEA for improving quality of life in cancer survivors." JAMA. DOI: 10.1001/jama.2010.1243.
  13. Yen SS et al. (1995). "Replacement of DHEA in aging men and women." Ann N Y Acad Sci. PMID: 8526330.
  14. Couzin-Frankel J (2013). "Aging genes: the sirtuin story unravels." Science. DOI: 10.1126/science.334.6060.1194.
  15. Verdin E (2015). "NAD+ in aging, metabolism, and neurodegeneration." Science. DOI: 10.1126/science.aac4854.
  16. Covarrubias AJ et al. (2021). "NAD+ metabolism and its roles in cellular processes during ageing." Nat Rev Mol Cell Biol. DOI: 10.1038/s41580-020-00313-x.
  17. Belsky DW et al. (2022). "Quantification of the pace of biological aging in humans through a blood test, the DunedinPoAm DNA methylation algorithm." eLife. DOI: 10.7554/eLife.73420.
  18. Lopez-Otin C et al. (2023). "Hallmarks of aging: An expanding universe." Cell. DOI: 10.1016/j.cell.2022.11.001.
  19. Rayman MP (2012). "Selenium and human health." Lancet. DOI: 10.1016/S0140-6736(11)61452-9.
  20. Loscalzo J (2014). "Oxidative stress in atherosclerosis." Arterioscler Thromb Vasc Biol. DOI: 10.1161/ATVBAHA.114.303038.
  21. Derosa G et al. (2016). "Effects of berberine on lipid profile in subjects with low cardiovascular risk." Expert Opin Biol Ther. PMID: 26950537.
  22. Plovier H et al. (2017). "A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice." Nat Med. DOI: 10.1038/nm.4236.
  23. Chandrasekaran A et al. (2019). "Role of Akkermansia muciniphila in metabolic disease." Gut Microbes. DOI: 10.1080/19490976.2019.1640587.
  24. Chen Y et al. (2023). "Hyperinsulinemia: an early biomarker of metabolic dysfunction." Front Clin Diabetes Healthc. PMC: PMC10186728. https://pmc.ncbi.nlm.nih.gov/articles/PMC10186728/
  25. American Gastroenterological Association (2024). "AGA Clinical Practice Update on Management of Iron Deficiency Anemia: Expert Review." Clin Gastroenterol Hepatol. https://www.cghjournal.org/article/S1542-3565(24)00410-5/fulltext
  26. Zeng J et al. (2025). "Role of Akkermansia muciniphila in insulin resistance." J Gastroenterol Hepatol. PMID: 39396929. https://pubmed.ncbi.nlm.nih.gov/39396929/
  27. Belsky DW et al. (2022). "DunedinPACE, a DNA methylation biomarker of the pace of aging." eLife. DOI: 10.7554/eLife.73420. PMC: PMC8853656. https://pmc.ncbi.nlm.nih.gov/articles/PMC8853656/
  28. Kim JH et al. (2023). "Relationship between Serum Cortisol, DHEAS Levels, and Natural Killer Cell Activity." PMC: PMC10299486. https://pmc.ncbi.nlm.nih.gov/articles/PMC10299486/
  29. American College of Cardiology (2025). "Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement." JACC. https://www.jacc.org/doi/10.1016/j.jacc.2025.08.047
  30. Zhang Z et al. (2025). "Efficacy of GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists in managing MAFLD." BMC Gastroenterol. https://link.springer.com/article/10.1186/s12876-025-04358-0

Medical Disclaimer

This report is generated for informational purposes only and does not constitute medical advice, diagnosis, or treatment. The analysis is based on available data and should be interpreted by qualified healthcare professionals in the context of the patient's complete medical history, physical examination, and clinical judgment.

All therapeutic recommendations should be discussed with and approved by the patient's treating physician before implementation. Supplement recommendations are based on available evidence but individual responses may vary. Some recommendations may require prescription medications that must be obtained through licensed healthcare providers.

The biomarker interpretations and clinical correlations presented here are based on current medical literature and guidelines, but medical knowledge evolves continuously. Reference ranges and clinical significance may vary between laboratories and patient populations.

Emergency Warning: If you are experiencing a medical emergency, please call emergency services immediately. Do not delay care based on this report.